Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine

Because of the advancement of personalized medicine in lung cancer, the subtyping of non–small cell lung cancer and predictive biomarker testing with fine‐needle aspiration and biopsy specimens have never been more important. The pathologist needs to efficiently handle these small specimens, report the diagnosis/subtype in a clinically relevant format, and evaluate the tissue adequacy for molecular testing.
Source: Cancer Cytopathology - Category: Pathology Authors: Tags: Commentary Source Type: research